<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911111-0048</DOCNO><DOCID>911111-0048.</DOCID><HL>   New Focus on AIDS   Boosts Health-Care,   Biotechnology Stocks</HL><DATE>11/11/91</DATE><SO>WALL STREET JOURNAL (J), PAGE C10</SO><CO>   CAR IMGN IMNR MEDI</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DRUG MANUFACTURERS (DRG)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)STOCK MARKET, OFFERINGS (STK)</IN><NS>STOCK andamp; OTHER MARKET NEWS (STK)</NS><RE>CALIFORNIA (CA)MASSACHUSETTS (MA)MARYLAND (MD)NORTH AMERICA (NME)NEW YORK (NY)PACIFIC RIM (PRM)UNITED STATES (US)</RE><LP>   NEW YORK -- Investors bid up the stocks of health-careproduct manufacturers and biotechnology companies withAIDS-related products in their research pipelines, hoping toprofit from heightened awareness of the disease in the wakeof basketball star Earvin &quot;Magic&quot; Johnson's announcement thathe is infected with the virus that causes the fatal disease.   Carter-Wallace Inc., the leading U.S. maker of condoms,soared more than $8 a share after a delayed opening, thenslipped back to close at $108, up $3.25.</LP><TEXT>   Immune Response Corp. leaped $3.50 to $57.50 in heavytrading. The San Diego-based company is testing a geneticallyengineered vaccine for patients who have the humanimmuno-deficiency virus that causes AIDS. The vaccine wouldtreat patients before they come down with symptoms ofacquired immune deficiency syndrome, and some investors sayit could be on the market in two years. With Immune Responsealready at lofty levels, biotech investor John Kaweske ofDenver's Financial Funds said he &quot;enjoyed the ride up&quot; butdidn't buy any more.   MedImmune Inc. vaulted $2.25 to $52.75. The Gaithersburg,Md., company has been developing genetically engineeredproducts targeted at the AIDS virus. It recently entered intoan agreement with Merck andamp; Co. to develop drugs that preventHIV infections.   ImmunoGen Inc. rose $2.50 to $21.25. The Cambridge, Mass.,company focuses on cancer treatments but recently announcedit was beginning tests on humans of a product designed totreat AIDS-related lymphoma.</TEXT></DOC>